Craft
  • Home
  •  / Adaptive Biotechnologies
Adaptive Biotechnologies

Adaptive Biotechnologies

Partners

125

FY, 2018

Revenue

$154.3 M

FY, 2021

Market Capitalization

$1.2 B

2022-11-18

Adaptive Biotechnologies Summary

Company summary

Overview
Adaptive Biotechnologies is a biotechnology company that focuses on adaptive immune systems. It develops a medicine platform that analyzes the genetic code of the immune system's defense against diseases. The company offers diagnosis and monitoring, and enables treatment of various diseases such as cancer, autoimmune disorders, and infectious diseases.
Type
Public
Status
Active
Founded
2009
HQ
Seattle, WA, US | view all locations
Website
http://adaptivebiotech.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key people

  • Chad Cohen

    Chad Cohen, Chief Financial Officer

  • Nancy Hill

    Nancy Hill, Executive Vice President, Operations & Program Management

  • Harlan Robins

    Harlan Robins, Chief Scientific Officer and Co-Founder

  • Chad Robins

    Chad Robins, Chief Executive Officer, Co-Founder, Chairman of the Board

Operating MetricsView all

Partners

125

FY, 2018

Immune Receptors Characteristics in Database

20B

FY, 2018

Product Lines

2

FY, 2018

LocationsView all

2 locations detected

  • Seattle, WA HQ

    United States

    1551 Eastlake Ave E #200

  • South San Francisco, CA

    United States

    2 Tower Pl UNIT 900

Adaptive Biotechnologies Financials

Summary financials

Revenue (Q3, 2022)
$47.8M
Gross profit (Q3, 2022)
$32.9M
Net income (Q3, 2022)
($45.3M)
EBIT (Q3, 2022)
($45.4M)

Footer menu